FDA Approves Lipfendra: A New Oral Treatment for High Cholesterol
On July 16, 2026, the Food and Drug Administration (FDA) announced the approval of Lipfendra (enlicitide), a groundbreaking oral medication for the treatment of high cholesterol, specifically targeting hypercholesterolemia and heterozygous familial hypercholesterolemia, a genetic condition that results in elevated cholesterol levels. Lipfendra marks a significant advancement as it is the first PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor available in pill form, prescribed in daily doses of 20 milligrams. This approval emphasizes the importance of combining Lipfendra with lifestyle modifications, including dietary interventions and increased physical activity, to optimize cholesterol management.
Familial hypercholesterolemia is a serious condition that, if untreated, can lead to severe cardiovascular issues such as heart attacks. Lipfendra operates by inhibiting the PCSK9 enzyme, which plays a crucial role in cholesterol regulation. By blocking this enzyme, Lipfendra helps lower levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad cholesterol," thereby reducing the risk of heart disease.
Dr. Nieca Goldberg, a board-certified cardiologist and clinical associate professor at NYU Grossman School of Medicine, explained that PCSK9 inhibitors work by preventing the breakdown of LDL receptors in the liver. This mechanism allows for more LDL receptors to remain available, enhancing the liver's ability to clear LDL cholesterol from the bloodstream. Daniel Atkinson, Clinical Lead at Treated.com, elaborated on this process, noting that liver cells utilize LDL receptors to capture and eliminate LDL cholesterol. When PCSK9 binds to these receptors, it prevents their recycling, leading to increased cholesterol levels in the blood.
Lipfendra binds to PCSK9 proteins, effectively blocking their action and preserving the LDL receptors necessary for cholesterol clearance. This innovative approach provides a non-invasive alternative to existing treatments, which often involve injections. The FDA's decision to approve Lipfendra was based on positive results from two randomized, double-blind, placebo-controlled clinical trials, CORALreef Lipids and CORALreef HeFH, which included 3,207 adults with severe high cholesterol. These trials demonstrated that Lipfendra could reduce LDL cholesterol levels by approximately 56% to 59%.
The introduction of Lipfendra offers a new option for patients who may struggle with current treatments for familial hypercholesterolemia, which often require invasive procedures or are difficult to tolerate. Traditional therapies have included injectable PCSK9 medications like Repatha and Praluent, which necessitate self-injections every few weeks. In contrast, Lipfendra's oral formulation simplifies treatment, as it can be taken daily and stored at room temperature.
While statins remain the first-line treatment for high cholesterol, Lipfendra provides an effective alternative for those who do not achieve adequate cholesterol reduction with statins alone or who experience side effects from them. Compared to other non-statin medications, Lipfendra offers superior efficacy in lowering LDL cholesterol. As the landscape of cholesterol management evolves, Lipfendra represents a significant step forward in providing accessible and effective treatment options for individuals with high cholesterol.




